CGON Stock Analysis: Buy, Sell, or Hold?
CGON - CG Oncology, Inc. Common stock
$66.25
5.17 (8.46%)
▲
5d:
+11.23%
30d:
+2.3%
90d:
+1.8%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: May 12, 2026
0d
Smart Money Distribution
None View Scanner →
Strength: 7.0/10
Get Alerted When CGON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CGON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: CGON shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: CGON is currently trading at $66.25, which is considered fair relative to its 30-day fair value range of $56.18 to $66.74.
Technical Outlook: Technically, CGON is in a uptrend. The price is approaching resistance at $66.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: CGON has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.29 (+36.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CGON is in a uptrend. The price is approaching resistance at $66.41. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 8.5% recently.
Market Sentiment: CGON has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $90.29 (+36.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$56.18 -
$66.74
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
92.1%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.5%)
- BULLISH: Trading 36.3% below Wall St target ($90.29)
Trading Range Analysis
30-Day Trading Range
$56.18 -
$66.74
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$53.21
Resistance Level
$66.41
Current Trend
Uptrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-23.84
Wall Street Target
$90.29
(+36.3%)
Revenue Growth (YoY)
1982.7%
Share & Embed Analysis
Last updated: June 23, 2026 9:42 AM ET
Data refreshes hourly during market hours. Next update: 10:42 AM
Data refreshes hourly during market hours. Next update: 10:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CGON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
James Mulay
SELL
15600 shares
2026-04-17
James Mulay
SELL
1964 shares
2026-03-16
James Mulay
SELL
11145 shares
2026-01-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 56 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 59 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
